Design and Rationale of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU). J of Skin. 2018;2(S1):S51. doi:10.25251/skin.2.supp.51